Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 2
2009 6
2010 6
2011 5
2012 7
2013 12
2014 8
2015 10
2016 10
2017 14
2018 13
2019 8
2020 10
2021 6
2022 9
2023 9
2024 15
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Among authors: bahleda r. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Lambotte O, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: bahleda r. Eur J Cancer. 2024 Jul;205:114075. doi: 10.1016/j.ejca.2024.114075. Epub 2024 May 4. Eur J Cancer. 2024. PMID: 38733717 Review.
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Facchinetti F, Hollebecque A, Braye F, Vasseur D, Pradat Y, Bahleda R, Pobel C, Bigot L, Déas O, Florez Arango JD, Guaitoli G, Mizuta H, Combarel D, Tselikas L, Michiels S, Nikolaev SI, Scoazec JY, Ponce-Aix S, Besse B, Olaussen KA, Loriot Y, Friboulet L. Facchinetti F, et al. Among authors: bahleda r. Cancer Discov. 2023 Sep 6;13(9):1998-2011. doi: 10.1158/2159-8290.CD-22-1441. Cancer Discov. 2023. PMID: 37377403 Free PMC article.
Immunothérapie des glioblastomes.
Baldini C, Romano PM, Varga A, Champiat S, Dumont S, Dhermain F, Louvel G, Marabelle A, Postel-Vinay S, Angevin E, Gazzah A, Ribrag V, Bahleda R, Michot JM, Hollebecque A, Soria JC, Massard C. Baldini C, et al. Among authors: bahleda r. Bull Cancer. 2018 Dec;105 Suppl 1:S59-S67. doi: 10.1016/S0007-4551(18)30391-6. Bull Cancer. 2018. PMID: 30595200 Review. French.
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs.
Henon C, Vibert J, Eychenne T, Gruel N, Colmet-Daage L, Ngo C, Garrido M, Dorvault N, Marques Da Costa ME, Marty V, Signolle N, Marchais A, Herbel N, Kawai-Kawachi A, Lenormand M, Astier C, Chabanon R, Verret B, Bahleda R, Le Cesne A, Mechta-Grigoriou F, Faron M, Honoré C, Delattre O, Waterfall JJ, Watson S, Postel-Vinay S. Henon C, et al. Among authors: bahleda r. Cell Rep Med. 2024 Jun 18;5(6):101582. doi: 10.1016/j.xcrm.2024.101582. Epub 2024 May 22. Cell Rep Med. 2024. PMID: 38781959 Free PMC article.
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Meric-Bernstam F, et al. Among authors: bahleda r. Cancer Discov. 2022 Feb;12(2):402-415. doi: 10.1158/2159-8290.CD-21-0697. Epub 2021 Sep 22. Cancer Discov. 2022. PMID: 34551969 Free PMC article. Clinical Trial.
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F, Loriot Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: bahleda r. Clin Cancer Res. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: bahleda r. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
131 results